ArriVent BioPharma, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q4 2023 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
ArriVent BioPharma, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q4 2023 to Q4 2024.
  • ArriVent BioPharma, Inc. Operating Lease, Right-of-Use Asset for the quarter ending December 31, 2024 was $154K, a 47.1% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 $154K -$137K -47.1% Dec 31, 2024 10-K 2025-03-03
Q3 2024 $187K Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $219K Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $250K Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $291K Dec 31, 2023 10-K 2025-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.